The Food and Drug Administration has approved Zanvastro, or zilganersen, for pediatric and adult patients with Alexander disease, making it the first FDA-approved treatment for the ultra-rare, progressive neurological disorder. The Sept. 3 decision gives families and clinicians an option intended to reduce production of the abnormal protein associated with the disease, rather than relying only on care for complications and symptoms.
The approval is a significant rare-disease milestone, but the evidence differs substantially across age groups. In a controlled study, patients old enough for certain motor testing showed benefits on measures of walking speed or broader motor skills. For children younger than 2, however, the FDA relied partly on drug-exposure modeling and safety observations in four treated patients, not on a concurrent controlled efficacy comparison.
What Zanvastro targets
Alexander disease is linked to mutations in the gene for glial fibrillary acidic protein, or GFAP. According to the FDA approval announcement, abnormal GFAP accumulates in support cells in the brain, damaging the nervous system over time. The disorder can lead to serious and potentially life-threatening neurological complications.
Zanvastro is an antisense oligonucleotide, a type of medicine designed to bind genetic material and alter production of a particular protein. In this case, it is intended to lower production of abnormal GFAP. It is administered into the spinal canal every three months by a trained health-care professional, rather than taken as a pill or given through a routine injection under the skin.
That mechanism is the basis for describing the therapy as directed at a disease-associated biological process. It does not mean the available trial results establish that the drug cures Alexander disease, reverses all neurological injury or improves survival. The FDA’s public summary reports specific motor-function findings, not long-term outcomes on those broader questions.
Trial results were measured differently by age
The agency evaluated Zanvastro in a multicenter randomized, controlled study, identified as NCT04849741, involving 49 patients ages 2 and older. It also considered an open-label substudy of four patients younger than 2. The controlled portion allows a stronger assessment of whether differences in the measured outcomes were caused by treatment than an uncontrolled observation would.
For participants 5 and older who had measurable walking difficulty at the start of the study, treated patients had significantly better walking speed than untreated patients at 61 weeks, the FDA said. That finding applies to the subgroup able to complete that assessment; it should not be read as evidence that every person with Alexander disease will have the same response.
Children ages 2 through 4 were assessed differently because walking speed was not considered a dependable outcome for that age group. Treated children improved on a broader motor-skills assessment while children in the control group declined, according to the FDA. The use of distinct endpoints reflects the practical challenge of studying a disorder that can affect patients at very different developmental stages.
For patients under 2, direct clinical evidence was much narrower. The FDA said the indication for that group was supported by pharmacokinetic modeling, which estimates how the drug is processed in the body, along with safety information from four treated infants and data from older children. There was no concurrent untreated comparison in that substudy, leaving greater uncertainty about the size and consistency of clinical benefit for the youngest patients.
A small program, with an unresolved count difference
The scale of the trial underscores the difficulty of producing evidence in an extremely rare disease. FDA’s description accounts for 53 participants: 49 in the study of patients 2 and older and four in the under-2 substudy. A University of Wisconsin–Madison account of the approval and research history describes the trial as involving 54 patients. The reason for that one-patient difference is not explained in the publicly available accounts.
Before the final review, Ionis had described the pivotal program as a global, multicenter, randomized, double-blind, controlled Phase 1-3 trial conducted at 13 sites in eight countries, with a 60-week double-blind treatment period. Its 2024 enrollment announcement said the core study enrolled people ages 2 to 65. The FDA’s later account is the clearest public description of the participants and findings considered for approval, though it does not resolve every difference from earlier company and university descriptions.
Researchers at Wisconsin said human testing began in 2021 after decades of laboratory work involving GFAP and the disease. The university credits research by Albee Messing and collaborators with helping advance the program, while Ionis Pharmaceuticals received the FDA approval.
Safety and treatment decisions
The FDA listed vomiting, back pain, cough, headache and post-lumbar-puncture syndrome among Zanvastro’s most common side effects. Aseptic meningitis, inflammation of the membranes around the brain and spinal cord that is not caused by a typical bacterial infection, has also been reported in treated patients.
Because treatment requires spinal-canal administration and the supporting evidence varies by age and baseline motor ability, suitability will require discussion with clinicians experienced in managing Alexander disease and in the procedure used to deliver the drug. Families and doctors will also have to weigh the reported motor findings against the uncertainties that remain about long-term outcomes and the youngest patients.